Adding pembrolizumab (Keytruda) to concurrent chemoradiotherapy in patients with high-risk locally advanced cervical cancer does not harm quality of life, according to patient-reported outcome ...

The FDA approved pembrolizumab (Keytruda) with chemoradiotherapy (CRT) for patients with stage III-IVA cervical cancer based on International Federation of Gynecology and Obstetrics (FIGO) 2014 ...

The addition of pembrolizumab to concurrent chemoradiotherapy conferred a statistically significant and clinically meaningful increase in PFS among women with newly diagnosed high-risk locally ...

Pembrolizumab (Keytruda) has picked up yet another cancer indication, this time for stage 3-4a cervical cancer in combination with chemoradiation therapy. The new US Food and Drug Administration (FDA) ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adding ...

Credit: Getty Images. The sBLA was based on efficacy and safety data from the KEYNOTE-A18 trial. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

There is a hint of major added benefit compared with chemotherapy with cisplatin or carboplatin, each plus paclitaxel with or without bevacizumab. These are the main first-line therapies for advanced ...

Please provide your email address to receive an email when new articles are posted on . The addition of pembrolizumab to chemoradiotherapy improved PFS and OS for women with high-risk, locally ...

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, ...

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and ...

Pembrolizumab has recently been approved in combination with chemotherapy for the treatment of women with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1. Chemotherapy ...